Notably, B16F10 melanoma cells express ATX at high levels but do not express LPAR1, indicating that the therapeutic success of combined inhibition of LPAR1 and ATX with Ki16425 and BMP22, respectively, in suppressing melanoma metastasis is due to targeting of the ATX-LPAR axis in both cancer and stromal cells. Here, LPAR1 is linked to cancer.